JPMorgan lowered the firm’s price target on Progyny to $49 from $57 and keeps an Overweight rating on the shares. The analyst assumes the company’s utilization patterns remain consistent going forward. The firm updated its model to account for Progyny’s new federal government plan which added 300,000 lives. It expects 20% revenue growth in 2024, and 21% EBITDA growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PGNY:
- Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Progyny price target lowered to $45 from $50 at KeyBanc
- Progyny sees FY23 revenue $1.087B-$1.1B, consensus 1.08B
- Progyny reports Q3 EPS 16c, consensus 12c
- Progyny, Inc. Announces Third Quarter 2023 Results